BioSpace News Archive

Policy

Biopharma Update on the Novel Coronavirus: April 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.

April 3, 2020
·
6 min read
·
BioSpace Editorial Staff
BioCapital

Compare Update: 2003 SARS Pandemic Versus 2020 COVID-19 Pandemic

SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.

April 3, 2020
·
5 min read
·
Gail Dutton
New Study Shows Possible Alternative Treatment for Unique Infant Tumors

The study reveals that brain tumors in babies are molecularly unique and could be candidates for targeted treatments.

April 3, 2020
·
3 min read
·
Michelle Brugioni
FDA

FDA Approves 1st COVID-19 Antibody Test

The U.S. Food and Drug Administration approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19.

April 3, 2020
·
3 min read
·
Mark Terry
Drug Development

Novartis and Incyte to Test Cancer Drug Jakavi in COVID-19

Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.

April 3, 2020
·
2 min read
·
Mark Terry
BioCapital

Experimental COVID-19 Vaccine Shows Promise in Producing Antibodies

When tested in mice, the vaccine, which is delivered through a fingertip-sized patch, produced the antibodies specific to the novel coronavirus that causes COVID-19.

April 3, 2020
·
2 min read
·
Alex Keown
Drug Development

Axon’s Tau Vaccine Shows Promise in Phase II Alzheimer’s Study

During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.

April 3, 2020
·
2 min read
·
Alex Keown
Business

Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen

Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.

April 3, 2020
·
2 min read
·
Alex Keown
BioCapital

Clinical Catch-Up: March 30 – April 3

This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

April 3, 2020
·
14 min read
·
Mark Terry
Business

Merit Medical Provides Historical Revenues In Revised Presentation Format

*Core revenue is a non-GAAP financial measure. A reconciliation of core revenue to GAAP revenue is included under the heading “Non-GAAP Financial Measures” below..

April 3, 2020
·
21 min read